Repositorio Digital

Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy

Mostrar el registro sencillo del ítem Debes, José Chan, Aaron Balderramo, Domingo Kikuchi, Luciana Gonzalez Ballerga, Esteban Prieto, John Tapias, Mónica Idrovo, Víctor Davalos, Milagros Cairo, Fernando Barreyro, Fernando Paredes, Sebastián Hernandez, Nelia Avendano, Karla Diaz Ferrer, Javier Yang, Ju Dong Carrera, Enrique Garcia, Jairo Mattos, Angelo Hirsch, Bruno Goncalves, Pablo Carrilho, Flair Roberts, Lewis 2019-03-22T19:13:00Z 2019-03-22T19:13:00Z 2018-05-01
dc.identifier.citation Liver Int. 2018 May;38(5):956-957 es_AR
dc.description Fil: Cairo, F. Hospital de Alta Complejidad en Red El Cruce Dr. Néstor C. Kirchner. Servicio de Gastroenterología. Florencio Varela, Argentina. es_AR
dc.description.abstract BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Most studies addressing the epidemiology of HCC originate from developed countries. This study reports the preliminary findings of a multinational approach to characterize HCC in South America. METHODS: We evaluated 1336 HCC patients seen at 14 centres in six South American countries using a retrospective study design with participating centres completing a template chart of patient characteristics. The diagnosis of HCC was made radiographically or histologically for all cases according to institutional standards. Methodology of surveillance for each centre was following AASLD or EASL recommendations. RESULTS: Sixty-eight percent of individuals were male with a median age of 64 years at time of diagnosis. The most common risk factor for HCC was hepatitis C infection (HCV, 48%), followed by alcoholic cirrhosis (22%), Hepatitis B infection (HBV, 14%) and NAFLD (9%). We found that among individuals with HBV-related HCC, 38% were diagnosed before age 50. The most commonly provided therapy was transarterial chemoembolization (35% of HCCs) with few individuals being considered for liver transplant (<20%). Only 47% of HCCs were diagnosed during surveillance, and there was no difference in age of diagnosis between those diagnosed incidentally vs by surveillance. Nonetheless, being diagnosed during surveillance was associated with improved overall survival (P = .01). CONCLUSIONS: Our study represents the largest cohort to date reporting characteristics and outcomes of HCC across South America. We found an important number of HCCs diagnosed outside of surveillance programmes, with associated increased mortality in those patients. es_AR
dc.language.iso en_US es_AR
dc.relation.ispartofseries Liver Int;2018 May;38(5):956-957
dc.subject Estudio Multicéntrico es_AR
dc.subject Carcinoma Hepatocelular es_AR
dc.subject Detección Precóz del Cáncer es_AR
dc.subject Neoplasias Hepáticas es_AR
dc.subject Valor Predictivo de las Pruebas es_AR
dc.subject América del Sur es_AR
dc.title Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy es_AR
dc.type Article es_AR

Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem